DOCSLIB.ORG

Parallel Import (PI) Licences Granted in August 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Parallel Import (PI) Licences Granted in August 2017 Parallel import (PI) licences granted in August 2017 PL Number Grant Date Licence Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status* PLPI 16369/1712 02/08/2017 G-PHARMA LIMITED PROGRAF 1MG HARD CAPSULES TACROLIMUS 1.000 MILLIGRAMMES POM PLPI 20492/0568 02/08/2017 CD PHARMA LIMITED ADALAT 10MG SOFT CAPSULES NIFEDIPINE 10.000 MILLIGRAMMES POM PLPI 20492/0568 02/08/2017 CD PHARMA LIMITED NIFEDIPINE 10MG SOFT CAPSULES NIFEDIPINE 10.000 MILLIGRAMMES POM PLPI 20636/2972 03/08/2017 STAR PHARMACEUTICALS LIMITED DEPIXOL 20 MG/ML SOLUTION FOR INJECTION FLUPENTIXOL DECANOATE 20.000 MILLIGRAMMES PER MILLILITRE POM PLPI 20636/2972 03/08/2017 STAR PHARMACEUTICALS LIMITED FLUPENTIXOL DECANOATE 20 MG/ML SOLUTION FOR INJECTION FLUPENTIXOL DECANOATE 20.000 MILLIGRAMMES PER MILLILITRE POM PLPI 20492/0567 09/08/2017 CD PHARMA LIMITED CANESTEN 2% W/W THRUSH CREAM CLOTRIMAZOLE 2 PERCENT WEIGHT IN WEIGHT P PLPI 20492/0567 09/08/2017 CD PHARMA LIMITED CLOTRIMAZOLE 2% W/W THRUSH CREAM CLOTRIMAZOLE 2 PERCENT WEIGHT IN WEIGHT P PLPI 20774/1526 09/08/2017 QUADRANT PHARMACEUTICALS LIMITED SERETIDE 500 ACCUHALER FLUTICASONE PROPIONATE 500 MICROGRAMMES POM PLPI 20774/1526 09/08/2017 QUADRANT PHARMACEUTICALS LIMITED SERETIDE 500 ACCUHALER SALMETEROL 50 MICROGRAMMES POM PLPI 33532/0723 09/08/2017 MPT PHARMA LIMITED MOVICOL PLAIN 13.7G SACHET, POWDER FOR ORAL SOLUTION MACROGOL 3350 13.125 GRAMMES P PLPI 33532/0723 09/08/2017 MPT PHARMA LIMITED MOVICOL PLAIN 13.7G SACHET, POWDER FOR ORAL SOLUTION POTASSIUM CHLORIDE 0.0502 GRAMMES P PLPI 33532/0723 09/08/2017 MPT PHARMA LIMITED MOVICOL PLAIN 13.7G SACHET, POWDER FOR ORAL SOLUTION SODIUM BICARBONATE 0.1786 GRAMMES P PLPI 33532/0723 09/08/2017 MPT PHARMA LIMITED MOVICOL PLAIN 13.7G SACHET, POWDER FOR ORAL SOLUTION SODIUM CHLORIDE 0.3508 GRAMMES P PLPI 39352/0379 09/08/2017 KOSEI PHARMA UK LIMITED ZINERYT ERYTHROMYCIN 40 MILLIGRAMMES PER MILLILITRE POM PLPI 39352/0379 09/08/2017 KOSEI PHARMA UK LIMITED ZINERYT ZINC ACETATE 12 MILLIGRAMMES PER MILLILITRE POM PLPI 39467/0273 09/08/2017 PILSCO LIMITED CONCERTA XL 18 MG PROLONGED RELEASE TABLETS METHYLPHENIDATE HYDROCHLORIDE 18.000 MILLIGRAMMES POM PLPI 40739/0134 09/08/2017 ENNOGEN HEALTHCARE LIMITED SEREVENT ACCUHALER SALMETEROL 50 MICROGRAMMES POM PLPI 15184/1707 16/08/2017 LEXON (UK) LIMITED TRENTAL 400MG MODIFIED RELEASE TABLETS PENTOXIFYLLINE 400.000 MILLIGRAMMES POM PLPI 19488/1825 16/08/2017 S AND M MEDICAL LIMITED LEVOCARNITINE PAEDIATRIC 30% ORAL SOLUTION LEVOCARNITINE 30 PERCENT WEIGHT IN VOLUME POM PLPI 20492/0545 16/08/2017 CD PHARMA LIMITED CONCERTA XL 27MG PROLONGED RELEASE TABLETS METHYLPHENIDATE HYDROCHLORIDE 27 MILLIGRAMMES POM PLPI 20492/0584 16/08/2017 CD PHARMA LIMITED HALF SINEMET CR 25 MG/100MG PROLONGED-RELEASE TABLETS CARBIDOPA 27 MILLIGRAMMES POM PLPI 20492/0584 16/08/2017 CD PHARMA LIMITED HALF SINEMET CR 25 MG/100MG PROLONGED-RELEASE TABLETS LEVODOPA 100 MILLIGRAMMES POM PLPI 20636/3015 16/08/2017 STAR PHARMACEUTICALS LIMITED ZOFRAN 4MG MELT ONDANSETRON 4 MILLIGRAMMES POM PLPI 39352/0385 16/08/2017 KOSEI PHARMA UK LIMITED FLUMETASONE PIVALATE/CLIOQUINOL 0.02% W/V / 1% W/V EAR DROPS SOLUTION CLIOQUINOL 1 PERCENT WEIGHT IN VOLUME POM PLPI 39352/0385 16/08/2017 KOSEI PHARMA UK LIMITED FLUMETASONE PIVALATE/CLIOQUINOL 0.02% W/V / 1% W/V EAR DROPS SOLUTION FLUMETHASONE PIVALATE 0.02 PERCENT WEIGHT IN VOLUME POM PLPI 39352/0385 16/08/2017 KOSEI PHARMA UK LIMITED LOCORTEN VIOFORM EAR DROPS CLIOQUINOL 1 PERCENT WEIGHT IN VOLUME POM PLPI 39352/0385 16/08/2017 KOSEI PHARMA UK LIMITED LOCORTEN VIOFORM EAR DROPS FLUMETHASONE PIVALATE 0.02 PERCENT WEIGHT IN VOLUME POM PLPI 46927/0018 16/08/2017 ORIFARM A-S DIPENTUM 500 MG TABLETS OLSALAZINE SODIUM 500 MILLIGRAMMES POM PLPI 46927/0018 16/08/2017 ORIFARM A-S OLSALAZINE SODIUM 500 MG TABLETS OLSALAZINE SODIUM 500 MILLIGRAMMES POM PLPI 40739/0117 17/08/2017 ENNOGEN HEALTHCARE LIMITED PROSTAP SR DCS 3.75 MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION LEUPRORELIN ACETATE 3.75 MILLIGRAMMES POM PLPI 20492/0593 18/08/2017 CD PHARMA LIMITED PAROXETINE 10MG TABLETS PAROXETINE HYDROCHLORIDE ANHYDROUS 11.11 MILLIGRAMMES POM PLPI 20636/3019 18/08/2017 STAR PHARMACEUTICALS LIMITED SECURON IV VERAPAMIL HYDROCHLORIDE 2.500 MILLIGRAMMES PER MILLILITRE POM PLPI 20636/3019 18/08/2017 STAR PHARMACEUTICALS LIMITED VERAPAMIL HYDROCHLORIDE 2.5 MG/ML SOLUTION FOR INJECTION VERAPAMIL HYDROCHLORIDE 2.500 MILLIGRAMMES PER MILLILITRE POM PLPI 33902/0640 18/08/2017 SAM PHARMA LIMITED AIRFLUSAL FORSPIRO 50 MICROGRAM/500 MICROGRAM PER ACTUATION INHALATION POWDER, PRE-DISPENSED FLUTICASONE PROPIONATE 500 MICROGRAMMES POM * POM = Prescription Only Medicine 1 P = Pharmacy G = General Sale List Parallel import (PI) licences granted in August 2017 PL Number Grant Date Licence Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status* PLPI 33902/0640 18/08/2017 SAM PHARMA LIMITED AIRFLUSAL FORSPIRO 50 MICROGRAM/500 MICROGRAM PER ACTUATION INHALATION POWDER, PRE-DISPENSED SALMETEROL XINAFOATE 73 MICROGRAMMES POM PLPI 15184/1687 21/08/2017 LEXON (UK) LIMITED FEMSEVEN CONTI 50 MICROGRAMS / 7 MICROGRAMS / 24 HOURS, TRANSDERMAL PATCH ESTRADIOL HEMIHYDRATE 50.000 MICROGRAMMES POM PLPI 15184/1687 21/08/2017 LEXON (UK) LIMITED FEMSEVEN CONTI 50 MICROGRAMS / 7 MICROGRAMS / 24 HOURS, TRANSDERMAL PATCH LEVONORGESTREL 7.000 MICROGRAMMES POM PLPI 20492/0544 21/08/2017 CD PHARMA LIMITED CONCERTA XL 18MG PROLONGED RELEASE TABLETS METHYLPHENIDATE HYDROCHLORIDE 18.000 MILLIGRAMMES POM PLPI 15814/1319 23/08/2017 OPD LABORATORIES LIMITED COSOPT PRESERVATIVE-FREE 20 MG/ML + 5 MG/ML EYE DROPS, SOLUTION, SINGLE DOSE CONTAINER DORZOLAMIDE HYDROCHLORIDE 22.26 MILLIGRAMMES PER MILLILITRE POM PLPI 15814/1319 23/08/2017 OPD LABORATORIES LIMITED COSOPT PRESERVATIVE-FREE 20 MG/ML + 5 MG/ML EYE DROPS, SOLUTION, SINGLE DOSE CONTAINER TIMOLOL MALEATE 6.83 MILLIGRAMMES PER MILLILITRE POM PLPI 21828/0716 23/08/2017 LANDMARK PHARMA LIMITED EQUASYM XL 10MG CAPSULES METHYLPHENIDATE HYDROCHLORIDE 10.000 MILLIGRAMMES POM PLPI 33532/0808 23/08/2017 MPT PHARMA LIMITED TRIMIPRAMINE 10MG FILM-COATED TABLETS TRIMIPRAMINE MALEATE 10.000 MILLIGRAMMES POM PLPI 39352/0380 23/08/2017 KOSEI PHARMA UK LIMITED IMIGRAN SUBJECT INJECTION SUMATRIPTAN 6 MILLIGRAMMES POM PLPI 39352/0380 23/08/2017 KOSEI PHARMA UK LIMITED SUMATRIPTAN 6MG/0.5ML INJECTION SUMATRIPTAN 6 MILLIGRAMMES POM PLPI 39352/0383 31/08/2017 KOSEI PHARMA UK LIMITED PROSTAP 3 DCS 11.25MG POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PRE FILLELEUPRORELIN ACETATE 11.25 MILLIGRAMMES PER MILLILITRE POM PLPI 39467/0305 31/08/2017 PILSCO LIMITED PROCYCLIDINE HYDROCHLORIDE 5 MG TABLETS PROCYCLIDINE HYDROCHLORIDE 5.00 MILLIGRAMMES POM PLPI 45310/0006 31/08/2017 PUREPHARM LIMITED FUSIDIC ACID 1% W/W VISCOUS EYE DROPS FUSIDIC ACID 1.000 PERCENT WEIGHT IN WEIGHT POM PLPI 46927/0010 31/08/2017 ORIFARM A-S FLORINEF 0.1MG TABLETS FLUDROCORTISONE ACETATE 0.1 MILLIGRAMMES POM PLPI 46927/0010 31/08/2017 ORIFARM A-S FLUDROCORTISONE ACETATE 0.1 MG TABLETS FLUDROCORTISONE ACETATE 0.1 MILLIGRAMMES POM * POM = Prescription Only Medicine 2 P = Pharmacy G = General Sale List .
Load more

Recommended publications
  • O SIEMSGLUSS IBERICA, S.A
    SIEMSGLUSS IBERICA, S.A. Product list G Memantine HCI Propylparaben Sodium Pharma APls Gemfibrozil Mepiramina Maleato R Gentian Powder Methoxsalen Ramipril Gentian Violet Methyl Nicotinate Ranitidin HCI Glibenclamide Methylprednisolone Base Rapamycin (Slrollrnus) Glimepiride Metimazole Resorcin A e Gluthatione reduced Metronidazol Resveratrol (Veri-Te®) 11 Alpha Hydroxyprogesterone Caffein Anhydrous Cyproterone Acetate Guaiacol Glyceril Ether Mexiletine HcI Rifampicin 17 Alpha Estradiol Calcipotriol Mieonazole Nitrate o H Roxythromycin Acetyl Salicylic Acid Canrenone Miltefosine Desonide Micronized Hydroquinone AcetylSpiramycin Cantharidin Minocycline HcI Dexamethasone BaseMicro Hyaluronic Acid Sodium Salt s Adapalene Captopril Minoxidil Seenidazol Dexamethasone Isonicotinate Miero Hydrochlorthiazide Amidopyrine Carbamazepine Mometasone Furoato Silver Sulfadiazine Dexamethasone Sodium Phosphate Hydrocortisone Acetate Micro Amikacin Sulphate Carbidopa Montelukast Sodium Simvastatine Dexketoprofen Trometamol Hydrocortisone BaseMicro Amiloride Carisoprodol Sodium Cefonicide Dextrometorphan Bromhidrate Hydroxyzine HcI N Amitriptyline HCI Carvedilol $pironolactone Micro Dextrose (Glucosa) Anhydrous N Aeetyl Glueosamine Amoxlcillin Na + Clavulonate K Cefaclor Monohidrate Sulpiride Diacethyl Naproxen Powder Ibuprofen Amoxicillin Na + Clavulonate K(5:1) Cefadroxil Compaeted Dielofenae Sodium Neutral Pellets Idebenone T Amoxicillin Trihydrate Compacted Cefalexine Monohydrate Powder Difenhydramire Nisin Taerollmus Monohydrate Imiquimod Amoxlcillln
    [Show full text]
  • RIEMSER Group International Product List
    RIEMSER Group International Product List Product Active substance Presentation Indication Product Category Channel EMB Fatol Ethambutol • POI 1g/10ml Treatment of several forms and stages of Anti-infectives Rx dihydrochloride • TAB 100mg tuberculosis • FCT 400, 500 mg Eremfat Rifampicin • GRA 1.2g/60ml Anti-infectives Rx • POI 300, 600mg Tuberculosis therapy , combination treatment of • FCT 150, 300, 450, 600 leprosy, prophylaxis for meningococcal meningitis, treatment of infections caused by nontuberculous mycobacteria Isozid Isoniazid • TAB 50, 100, 200 mg During Chemotherapy, -prophylaxis and - Anti-infectives Rx • POI 500mg prevention for / of tuberculosis Isozidcomp Isoniazid / pyridoxine • TAB 100mg / 20mg Chemotherapy, -prophylaxis and -prevention for / Anti-infectives Rx • FCT 200mg /40 mg, 300mg/60mg of Tuberculosis PAS-Fatol Sodium aminosalicylate • POI 13.49g Chemotherapy for tuberculosis, caused by Anti-infectives Rx dihydrate mycobacterium tuberculosis and mycobacterium bovis. Peteha Protionamide • FCT 250mg Treatment of tuberculosis, leprosy and diseases Anti-infectives Rx caused by so-called ubiquitours (atypical) mycobacteria Pyrafat Pyrazinamide • FCT 500mg Combination therapy for all types of tuberculosis, Anti-infectives Rx • TAB 500mg caused by mycobacterium tuberculosis, mycobacterium africanum, or mycobacterium microtti. Terizidon Terizidone • CAP 250mg Treatment of tuberculosis caused by Anti-infectives Rx mycobacterium tuberculosis Vancomycin Enterocaps Vancomycin • CAP 250 mg Treatment of certain types of bowel
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • EAR, NOSE and OROPHARYNX Updated: October 2020
    Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY CHAPTER 12: EAR, NOSE AND OROPHARYNX Updated: October 2020 The following prescribing guidelines are relevant to the ENT chapter and can be found here: • Allergic Rhinitis in adults and adolescents over 12 years of age • Management of chronic rhinosinusitis with or without nasal polyps 12.1 DRUGS ACTING ON THE EAR 12.1.1 Otitis externa Investigation is not routinely recommended for the initial diagnosis of otitis externa. Group Drug Astringent/acidic Acetic acid 2% ear spray preparations Self-care: patients are advised to purchase this over the counter Gentamicin 0.3% ear/eye drops* Antibiotic preparations Ciprofloxacin 2mg/ml ear drops 0.25ml unit dose PF Betnesol-N ear/eye/ nose drops* Combined corticosteroid (Betamethasone 0.1% & neomycin 0.5%) and aminoglycoside Otomize ear spray* antibiotic preparations (Dexamethasone 0.1%, neomycin 0.5% & acetic acid 2%) Corticosteroid Prednisolone 0.5% ear/eye drops Lower potency preparations Betamethasone 0.1% ear/eye/ nose drops Higher potency Antifungal preparations Clotrimazole 1% solution 20ml (with dropper) * In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides in patients with a perforated tympanic membrane (eardrum) or patent grommet. 1. The following are GREY, not for first line empirical use, and should only be used when sensitivity is confirmed through swab results- • Hydrocortisone acetate 1%/gentamicin 0.3% ear drops • Flumetasone pivalate 0.02%/clioquinol 1% ear drops 2. How should I treat acute diffuse otitis externa? (CKS) • Remove or treat any precipitating or aggravating factors. • Prescribe or recommend a simple analgesic for symptomatic relief.
    [Show full text]
  • Ear, Nose and Oral Cavity
    NHS Borders Joint Prescribing Formulary Ear, nose, and oral cavity Black Text Drugs which may be prescribed by all prescribers Drugs which are either for specialist only prescription or for specialist Pink Text initiation, with prescribing transfer to GP Important Information: In addition to the disclaimer on NHS Borders website the following information is included confirming that the information contained in NHS Borders Joint Prescribing formulary is drawn from several sources, including BNF & BNF for children, product SPCs, local and national guidelines, local expert opinion, Lothian Joint Formulary and these are all gratefully acknowledged here. NHS Borders has done its utmost to ensure the information in the BJF is accurate and reliable, but NHS Borders cannot guarantee that the information is complete and accurate. Prescribers are referred to the SPCs, BNF and BNF for children to confirm prescribing information. June 2021 Contents Page Table of Contents 12.1 Drugs acting on the ear ................................................................................................ 3 Otitis externa ................................................................................................................ 3 Otitis media .................................................................................................................. 3 Removal of ear wax ..................................................................................................... 3 12.2 Drugs acting on the nose ............................................................................................
    [Show full text]
  • Parallel Import (PI) Licences Granted in May 2017
    Parallel import (PI) licences granted in May 2017 PL Number Grant Date Licence Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status* PLPI 15184/1699 03/05/2017 LEXON (UK) LIMITED TIMOPTOL UNIT DOSE 0.25% W/V EYE DROPS SOLUTION TIMOLOL 2.5 MILLIGRAMMES PER MILLILITRE POM PLPI 15184/1700 03/05/2017 LEXON (UK) LIMITED TIMOPTOL UNIT DOSE 0.5% W/V EYE DROPS SOLUTION TIMOLOL 0.5 MILLIGRAMMES PER MILLILITRE POM PLPI 16369/1716 03/05/2017 G-PHARMA LIMITED CELIPROLOL HYDROCHLORIDE 200MG TABLETS CELIPROLOL HYDROCHLORIDE 200.000 MILLIGRAMMES POM PLPI 21828/0717 03/05/2017 LANDMARK PHARMA LIMITED LEVOCARNITINE PAEDIATRIC 30% ORAL SOLUTION LEVOCARNITINE 30.00 PERCENT WEIGHT IN VOLUME POM PLPI 33532/0768 03/05/2017 MPT PHARMA LIMITED COLESTYRAMINE SUGAR FREE 4G-SACHET COLESTYRAMINE 4.000 GRAMMES POM PLPI 33532/0768 03/05/2017 MPT PHARMA LIMITED QUESTRAN LIGHT 4G-SACHET POWDER FOR ORAL SUSPENSION COLESTYRAMINE 4.000 GRAMMES POM PLPI 33532/0778 03/05/2017 MPT PHARMA LIMITED SERETIDE 500 ACCUHALER FLUTICASONE PROPIONATE 500.00 MICROGRAMMES POM PLPI 33532/0778 03/05/2017 MPT PHARMA LIMITED SERETIDE 500 ACCUHALER SALMETEROL XINAFOATE 0.0725 MILLIGRAMMES POM PLPI 33532/0779 03/05/2017 MPT PHARMA LIMITED TRIMIPRAMINE 25MG FILM-COATED TABLETS TRIMIPRAMINE MALEATE 34.9 MILLIGRAMMES POM PLPI 39352/0376 03/05/2017 KOSEI PHARMA UK LIMITED DESMOPRESSIN ACETATE 0.1MG TABLETS DESMOPRESSIN ACETATE 0.1 MILLIGRAMMES POM PLPI 39352/0377 03/05/2017 KOSEI PHARMA UK LIMITED FLUMETASONE PIVALATE/CLIOQUINOL 0.02% W/V / 1% W/V EAR DROPS SOLUTION CLIOQUINOL
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Queensland Health List of Approved Medicines
    Queensland Health List of Approved Medicines Drug Form Strength Restriction abacavir * For use in accord with PBS Section 100 indications * oral liquid See above 20 mg/mL See above tablet See above 300 mg See above abacavir + lamivudine * For use in accord with PBS Section 100 indications * tablet See above 600 mg + 300 mg See above abacavir + lamivudine + * For use in accord with PBS Section 100 indications * zidovudine tablet See above 300 mg + 150 mg + 300 mg See above abatacept injection 250 mg * For use in accord with PBS Section 100 indications * abciximab (a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * injection See above 10 mg/5 mL See above abiraterone For use by medical oncologists as per the PBS indications for outpatient and discharge use only tablet See above 250 mg See above 500 mg See above acamprosate Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. enteric tablet See above 333 mg See above acarbose For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents tablet See above 50 mg See above 100 mg See above acetazolamide injection 500 mg tablet 250 mg acetic acid ear drops 3% 15mL solution 2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL Generated on: 30-Aug-2021 Page 1 of 142 Drug Form Strength Restriction acetylcysteine injection For management of paracetamol overdose 2 g/10 mL See above 6 g/30 mL See above aciclovir cream Infectious disease physicians, haematologists and oncologists 5% See above eye ointment For use on the advice of Ophthalmologists only.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Wo 2009/139817 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 19 November 2009 (19.11.2009) WO 2009/139817 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/4709 (2006.01) C07D 405/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) Number: International Application CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, PCT/US2009/002391 EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 15 April 2009 (15.04.2009) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (25) Filing Language: English NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (26) Publication Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/045,142 15 April 2008 (15.04.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): SAR- GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, CODE CORPORATION [US/US]; Suite 505, 343 San- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, some Street, San Francisco, CA 94104 (US).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,955,618 B2 Metselaar Et Al
    US007955618B2 (12) United States Patent (10) Patent No.: US 7,955,618 B2 Metselaar et al. (45) Date of Patent: Jun. 7, 2011 (54) COMPOSITION FORTREATMENT OF FOREIGN PATENT DOCUMENTS NFLAMMLATORY DSORDERS EP O 622 O72 A2 3, 1994 EP O 622 O72 B1 11, 1994 EP 1 O72 617 A1 7, 1999 (75) Inventors: Josbert Maarten Metselaar, Utrecht EP 1044 679 A1 * 10/2000 (NL); Marca Henriette M. Wauben, EP 1 190 706 * 3f2OO2 Utrecht (NL); Gerrit Storm, Utrecht EP 1 190 706 A1 3, 2002 (NL) JP 62-42733 2, 1987 WO WO94,07466 * 4f1994 WO WO94,07466 4f1994 (73) Assignee: Enceladus Pharmaceuticals B.V., WO WO94,07468 4f1994 Amsterdam (NL) WO WO9842.283 10, 1998 WO WO98 50040 11, 1998 WO WO98 50041 11, 1998 (*) Notice: Subject to any disclaimer, the term of this WO WOOO,25748 A1 5, 2000 patent is extended or adjusted under 35 WO WOOO.38653 T 2000 U.S.C. 154(b) by 182 days. WO WOO2,45688 A2 12/2001 WO WOO2,45688 A2 6, 2002 WO WOO3,105805 A1 12/2003 (21) Appl. No.: 10/455.257 WO WO 2004 O19916 A1 3, 2004 OTHER PUBLICATIONS (22) Filed: Jun. 5, 2003 PCT International Search Report, PCT/EPO 1/14633, dated May 8, 2002, 2 pages. (65) Prior Publication Data PCT International Preliminary Examination Report, PCT/EP01/ US 2004/OO37875A1 Feb. 26, 2004 14633, dated Apr. 2, 2003, 2 pages. Al-Muhammad et al., Studies on the formulation and in vitro release of ophthalmic liposomes containing dexamethasone sodium phos Related U.S.
    [Show full text]
  • Queensland Ambulance Service Isolated Practice Area Paramedic
    Health (Drugs and Poisons) Regulation 1996 Drug Therapy Protocol – Queensland Ambulance Service Isolated Practice Area Paramedic Chief Medical Officer and Healthcare Regulation Branch Healthcare Approvals and Regulation Unit PO Box 21 Fortitude Valley BC QLD 4006 Telephone (07) 3708 5264 Facsimile (07) 3708 5431 Disclaimer: Please note that any material printed is regarded as an uncontrolled copy. It is the responsibility of the person printing the document to refer frequently to https://www.health.qld.gov.au/system- governance/licences/medicines-poisons/legislation-standards/acts-regulation for updates Health (Drugs and Poisons) Regulation 1996 Drug Therapy Protocol – Queensland Ambulance Service Isolated Practice Area Paramedic I, Jeannette Rosita Young, pursuant to the Health (Drugs and Poisons) Regulation 1996, sections 66(4)(c)(ii),174(2A)(c)(ii) and 262(2)(c) certify this document as the Drug Therapy Protocol – Queensland Ambulance Service Isolated Practice Area Paramedic. Circumstances and conditions 1. An isolated practice area paramedic performing ambulance duties for the Queensland Ambulance Service may administer or supply a controlled or restricted drug or scheduled poison listed in Appendix 1, column 1 only: 1.1 by a route of administration for the drug stated in Appendix 1, column 2; and 1.2 subject to the conditions for the drug stated in Appendix 1, column 3 (if any); and 1.3 in accordance with a Health Management Protocol developed and approved by the Queensland Ambulance Service that meets the requirements in Appendix 2 (the relevant protocol).1 2. The relevant Health Management Protocol and Australian Immunisation Handbook must be available to the isolated practice area paramedic at the time the isolated practice area paramedic is acting under this Drug Therapy Protocol.
    [Show full text]